Clinical Trial Update: A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated tolerability and the effects of three single-dose regimens of BIA 9-1067 in Parkinson's disease, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 9-1067

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2015-01-12